Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. Tasian and his research team use an epidemiologic framework, including randomized trials and multi-institutional observational studies, to examine the etiology of kidney stone disease and the comparative effectiveness of surgical interventions. He also employs machine learning of complex data to improve diagnosis, risk stratification, and prediction of treatment response for children and adults with benign urologic disease.
Dr. Gottardi leads the Bioengineering and Biomaterials (Bio2) lab, collaborating on clinical and research efforts to offer engineering solutions for pediatric health, primarily treatments for airway disorders. Dr. Gottardi researches mechanisms of laryngotracheal pathologies, applies tissue engineering to improve pediatric conditions, develops new devices, and formulates controlled drug delivery systems to treat and improve patients’ lives.